Bias or biology: Evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome

Journal of Rheumatology

Volumn 23, Issue SUPPL. 46, 1996, Pages 60-72

  Horwitz, Ralph I ^a,c   Daniels, Stephen R ^a,b  

^a Gran Tokyo South Tower   (Japan)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

diagnosis; eosinophilia myalgia syndrome; epidemiology; L tryptophan

Indexed keywords

TRYPTOPHAN;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EOSINOPHILIA MYALGIA SYNDROME; HUMAN; PRIORITY JOURNAL; ARTICLE; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; EPIDEMIOLOGY; METHODOLOGY; OBSERVER VARIATION;

CASE-CONTROL STUDIES; EOSINOPHILIA-MYALGIA SYNDROME; EPIDEMIOLOGIC METHODS; HUMANS; OBSERVER VARIATION; RESEARCH DESIGN; TRYPTOPHAN;

EID: 0030255323     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Hertzman PA, Blevins WL, Mayer J, Greenfield B, Ting M, Gleich GJ: Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med 1990;322:869-73.
2. Swygert LA, Maes EF, Sewell LE, Miller L, Falk H, Kilbourne EM: Eosinophilia-myalgia syndrome. Results of national surveillance. JAMA 1990;264:1698-703.
3. Eidson M, Philen RM, Sewell CM, Voorhees R, Kilbourne EM: L-tryptophan and eosinophilia-myalgia syndrome in New Mexico. Lancet 1990;335:645-8.
4. Eosinophilia-myalgia syndrome and L-tryptophan-containing products - New Mexico, Minnesota, Oregon, and New York, 1989. MMWR Morbid Mortal Wkly Rep 1989;38:785-8.
5. Slutsker L, Hoesly FC, Miller L, Williams LP, Watson JC, Fleming DW: Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer. JAMA 1990;264:213-7.
6. Belongia EA, Hedberg DW, Gleich GJ, et al: An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 1990;323:357-65.
7. Kamb ML, Murphy JJ, Jones JL, et al: Eosinophilia-myalgia syndrome in L-tryptophan exposed patients. JAMA 1992;267:77-82.
8. Horwitz RI, Feinstein AR: Methodologic standards and contradictory results in case-control research. Am J Med 1979;66:556.
9. Feinstein AR, Horwitz RI: Double standards, scientific methods and epidemiologic research. N Engl J Med 1982;307:1611-7.
10. Hertzman PA: Criteria for the definition of eosinophilia-myalgia syndrome. J Rheumatol 1996;(suppl 46)23:7-12.
11. Spitzer WO, Haggerty J, Tamblyn R, Berkson L, Elmore J, Horwitz RI: Continuing occurrence of eosinophilia-myalgia syndrome. Br J Rheumatol (In Press).
12. Back EE, Henning KJ, Kallenbach LR, Brix KA, Gunn RA, Mellius JM: Risk factors for developing eosinophilia-myalgia syndrome among L-tryptophan users in New York. J Rheumatol 1993;20:666-72.
13. Wagner KR, Elmore JG, Horwitz RI: Diagnostic bias and the eosinophilia-myalgia syndrome (abstr). J Gen Intern Med 1994;(suppl 2)9:37.
14. Horwitz RI, Feinstein AR: Exclusion bias and the false relationship of reserpine and breast cancer. Arch Intern Med 1985;145:1873-5.
15. Shapiro S: L-tryptophan and eosinophilia-myalgia syndrome. Lancet 1994;343:1035-6.
16. Deposition of Edward A. Belongia, MD (December 15, 1993), In Re L-tryptophan. Minnesota Department of Health. No. 865, p 329-31, Exhibit 28.
17. Deposition of Edward A. Belongia, MD (December 15, 1993), In Re L-tryptophan, M.D.L. No. 865, p. 343-4, Exhibit 32.
18. Caudill S, Hill RH, Philen RM, et al: Important issues affecting eosinophilia-myalgia syndrome investigations based on analyses of L-tryptophan samples. J Occup Med Toxicol 1993;2:41-52.
19. Kilbourne EM: Eosinophilia-myalgia syndrome: Coming to grips with a new illness. Epidemiol Rev 1992;14:16-36.
20. Philen R, Hill RH, Flanders WD, et al: Tryptophan contaminants associated with eosinophilia-myalgia syndrome. Am J Epidemiol 1993;3:154-9.
21. Deposition of David W. Fleming, MD (June 30, 1993), In Re L-tryptophan M.D.L. No. 865, Exhibits 426, 495.
22. Deposition of David W. Fleming, MD (June 30, 1993), In Re L-tryptophan, M.D.L. No. 865, Exhibit 503.
23. Deposition of David W. Fleming, MD (June 30, 1993), In Re L-tryptophan, M.D.L. No. 865, Exhibit 507.
24. Deposition of David W. Fleming, MD (June 30, 1993), In Re L-tryptophan, M.D.L. No. 865, Exhibit 515.
25. Deposition of David W. Fleming, MD (June 30, 1993), In Re L-tryptophan, M.D.L. No. 865, Exhibit 521.
26. Deposition of J. Christopher Caston, MD (May 26, 1993-July 30, 1993), In Re L-tryptophan, M.D.L. No. 865, p. 450-6, Exhibit 79.
27. Deposition of J. Christopher Caston, MD (May 26, 1993-July 30, 1993), In Re L-tryptophan, M.D.L. No. 865, p. 152-64, 426-9.
28. Deposition of J. Christopher Caston, MD (May 26, 1993-July 30, 1993), In Re L-tryptophan, M.D.L. No. 865, p. 318-403.
29. Deposition of J. Christopher Caston, MD (May 26, 1993-July 30, 1993), In Re L-tryptophan, M.D.L. No. 865, p. 380-4, Exhibits 37-40.
30. Deposition of J. Christopher Caston, MD (May 26, 1993-July 30, 1993), In Re L-tryptophan, M.D.L. No. 865, p. 385-8, Exhibits 41-45.
31. Deposition of J. Christopher Caston, MD (May 26, 1993-July 30, 1993), In Re L-tryptophan, M.D.L. No. 865, p. 388-93, Exhibits 46-50.
32. Deposition of J. Christopher Caston, MD (May 26, 1993-July 30, 1993), In Re L-tryptophan, M.D.L. No. 865, p. 394, Exhibits 52-53.
33. Deposition of J. Christopher Caston, MD (May 26, 1993-July 30, 1993), In Re L-tryptophan, M.D.L. No. 865, p. 321.
34. Deposition of J. Christopher Caston, MD (May 26, 1993-July 30, 1993), In Re L-tryptophan, M.D.L. No. 865, p. 199-201.
35. Deposition of J. Christopher Caston, MD (May 26, 1993-July 30, 1993), In Re L-tryptophan, M.D.L. No. 865, p. 203-5.
36. Caston J, Roufs JB, Forgarty CM, Applebaum ML, Smith WP Jr, Littlefield RH: Treatment of refractory eosinophilia-myalgia syndrome associated with the ingestion of L-tryptophan containing products. Adv Ther 1990;7:206-28.
37. Henning K, Jean-Baptiste E, Singh T, Hill RH, Friedman SM: Eosinophilia-myalgia syndrome in patients ingesting a single source of L-tryptophan. J Rheumatol 1993;20:273-8.